ApoE gene-silencing divalent siRNAs (Atalanta Therapeutics/Genentech)

N/A

Report date: 2025/03/14 18:14:27
NME

Base Information

Drug NameApoE gene-silencing divalent siRNAs (Atalanta Therapeutics/Genentech)
Drug Alias Namedi-siRNA targeting ApoE (Atalanta Therapeutics/Genentech)RNAi therapeutics (Atalanta Therapeutics/Genentech)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionApolipoprotein E inhibitors
TargetsApolipoprotein E
Therapy Area/IndicationsNerve DegenerationAmyotrophic Lateral SclerosisAlzheimer Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAtalanta Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesAtalanta TherapeuticsGenentech Inc
Inactive CompaniesN/A
Active IndicationsNerve DegenerationAmyotrophic Lateral SclerosisAlzheimer Disease +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A